



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Fatal HBoV-1 infection in adult female cystic fibrosis patient



Doris Dieninghoff, MD ^{a,1}, Christian Karagiannidis, MD ^{a,1}, Stephan Straßmann, MD ^{a,1}, Monika Pieper ^b, Sarah Dammaschek ^b, Joseph Zabner, MD ^c, Aloysius Klingelutz, PhD ^c, Wolfram Windisch, MD ^a, Michael Brockmann, MD ^b, Oliver Schildgen, PhD ^{b,*}, Verena Schildgen, PhD ^b

^a Department of Pneumology, Kliniken der Stadt Köln gGmbH, Cologne, University of Witten/Herdecke, Germany

^b Institut für Pathologie, Klinikum der Privaten Universität Witten/Herdecke mit Sitz in Köln, Cologne, Germany

^c University of Iowa Carver College of Medicine, IA, USA

ARTICLE INFO

Article history:

Received 27 May 2016

Received in revised form 6 July 2016

Accepted 11 July 2016

ABSTRACT

A clinical case of fatal HBoV infection in an adult cystic-fibrosis patient awaiting lung transplantation is reported. The case is important as the genetic background of the underlying disease is congruent with the background of the sole permissive permanent cell culture CuFi-8 which originates also from a CF patient donor.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The human bocavirus (HBoV) is a parvovirus that is associated with acute and chronic infections of the upper and lower respiratory tract, persists in some tissues and solid cancers and putatively may play an aetiologic role in the development of idiopathic lung fibrosis [1–8]. The viral infection can switch between long term periods of viral shedding and silent phases of latency [9]. To date, no animal model exists, thus studies on the pathology of HBoV infections are limited to clinical studies, case descriptions, and air-liquid interface cell culture models that have been shown to mimic some important steps of the infection cycle [1,7,10–12]. The latter infections models are based on either primary cells that can be differentiated into organ like tissues from primary cells [1,7,11–13] or CuFi-8 cells [1,10,13]. CuFi-8 is a cell line derived from a 24 year old female patient suffering from cystic fibrosis; the cell line carries the mutation pattern $\Delta F508/\Delta F508$ (the most common CF associated mutation) and is an immortalized human epithelial airway cell line from the bronchus of the patient; the immortalization was performed with Weinberg hTERT and HPV-16 E6/E7 [10,14].

This information might be relevant for a current clinical case that was treated in our hospital in Cologne. The patient was a 24 year old non-smoking Caucasian cystic fibrosis patient. She was regularly treated in our cystic fibrosis outclinics and was deemed to be eligible for lung transplantation shortly before the fatal clinical episode started. In advance to the lung transplantation, a microbiological check-up revealed

colonization of the lung with low titres of *Aspergillus* and a multi-resistant *Pseudomonas aeruginosa* strain, combined with allergic asthma, pancreatic insufficiency, and malnutrition (BMI 14–15 kg/m²). In order to overcome the malnutrition, percutaneous endoscopic gastrostomy (PEG) was required and initiated in our hospital. The patient started to recover well, episodically required non-invasive ventilation (NIV), but was in a condition stable enough to continue NIV at home. The night before the patient should have left the hospital she developed an ARDS unexpectedly and was shifted to our intensive care unit. During intensive care treatment, despite expected obstipation, the patient developed massive diarrhea. In order to identify a pathogen causative for the ARDS, a BAL was performed and analysed for respiratory bacteria and viruses. An all-embracing molecular and microbiological diagnostic algorithm was performed as described earlier [15–17], including molecular screening for human herpesviruses 1–8, Parechoviruses, Rhino- and Enteroviruses, Adenoviruses, Influenza A and B virus including H1N1, Human metapneumovirus, respiratory syncytial virus A and B, Coronaviruses 229E, OC43, HKU-1, NL63, parainfluenzaviruses 1–4, mumps and measles, and human bocavirus, *Mycoplasma pneumoniae*, *Chlamydomphila pneumoniae*, *Legionella pneumophila*, and *Bordetella pertussis*, but revealed human bocavirus as the sole pathogen detectable in the BAL during the fatal clinical flare of the ARDS. Detailed protocols for the diagnostic procedures were published previously [1,9,16–18]. Moreover, any attempts to culture further respiratory pathogens including *Mycobacterium tuberculosis* and atypical mycobacteria revealed negative results.

Although the clinical course could have been triggered by the *Pseudomonas aeruginosa* or *Aspergillus* colonization and no *Pseudomonas cepacia* infection was differentially excluded, the most likely explanation for the fatal outcome remains the sole infection with human bocavirus. In this context it is important to note, that the patient was

* Corresponding author at: Kliniken der Stadt Köln gGmbH, Krankenhaus Merheim, Klinikum der Privaten Universität Witten/Herdecke, Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Köln (Cologne), Germany.

E-mail address: schildgeno@kliniken-koeln.de (O. Schildgen).

¹ These authors contributed equally to the clinical part of this case report.

homozygous for the cystic fibrosis genotype $\Delta F508/\Delta F508$, and as the donor of the CuFi-8 cell line, at the time point of death was 24 years of age. It is important to mention, that the BAL was characterized by serious bleeding, which may have contributed to the clinical outcome. This bleeding is another parallel to the CuFi-8 cells: The cells are permissive for HBoV if they are seeded to filter membranes and differentiated to pseudostratified air-liquid interface cultures; thereby, they fall dry and develop a mucus layer on top, while receiving nutrition from the basal medium. If those air-liquid interface cultures are infected with HBoV they develop a serious cytopathic effect and may become “leaky”, i.e. the basal cell culture medium passes the membrane, which can be compared to the clinical bleeding. The fact that age, sex, and genetic phenotype for the patient and the permissive CuFi-8 cell culture were equal solicits the cautious conclusion that the patient was highly permissive for the HBoV infection and died because of the serious damages the virus initiated. This hypothesis is further supported by the fact that the patient suffered from diarrhea, although cystic fibrosis in concert with pancreatic insufficiency is generally accompanied by obstipation. In this context it is important to mention that HBoV-1 is not generally associated with diarrhea but is observed in HBoV-2 and 3 infections [19–22]; however, HBoV-1 can be shed via the gastrointestinal route after swallowing and was repeatedly found in colorectal malignancies [23,24]. Unfortunately, due to the fact that the clinical course progresses so rapidly, and that the clinical colleagues were not aware of the parallels between the genetic background of the CuFi-8 cells and the patient, no further clinical specimen were collected for scientific purposes, thus no further laboratory investigations could be performed, although this would not have changed the clinical decision making. This is a considerable limitation of our report, which in our view still contains important hints regarding the pathogenesis of HBoV.

Taking into account the fact that it remains formally difficult to attribute clinical causalities to human bocavirus as previously discussed by Martin [25] and Byington [26], a permissive animal model for studying HBoV pathology would be a great advantage. However, although exclusively investigating a clinical cohort, Byington [26] and coworkers have unintentionally confirmed the assumption that HBoV is indeed a true pathogen rather than a blind and silent passenger [27], which was further confirmed by our recent translation study in which we have shown that HBoV-1 induces a profibrotic and procancerogenic cytokines expression *in vivo* and *in vitro* [1].

We also have to critically discuss the putative link between the CF genotype of the patient and the cell culture and its relation to the severe outcome of the HBoV infection. So far it remains a matter of speculation if there is a causality between these co-occurrences or if the clinical case was just a rare event that was congruent to our observations in cell culture. However, it remains possible that such a causative link exists and therefore this clinical case presentation is intended to trigger further research in this direction.

As a consequence, more detailed clinical studies that focus on the high risk group of cystic fibrosis patients suffering from HBoV infections are required, and it needs to be tested *in vitro* if cystic fibrosis specific factors contribute to a more severe clinical course of the HBoV infection of those patients.

Ethical approval

All procedures described in this case report were performed with approval from the Ethic Committee of the University of Witten (vote 73/2012).

Conflict of interest declaration

The authors declare that no conflict of interest apply according to the ICMJE definitions.

Funding

No funding was available for this report.

References

- [1] S. Khalfaoui, V. Eichhorn, C. Karagiannidis, I. Bayh, M. Brockmann, M. Pieper, et al., Lung infection by human bocavirus induces the release of profibrotic mediator cytokines *in vivo* and *in vitro*, *PLoS One* 11 (1) (2016), e0147010.
- [2] V. Schildgen, S. Khalfaoui, O. Schildgen, Human bocavirus: from common cold to cancer? Speculations on the importance of an episomal genomic form of human bocavirus, *Rev. Med. Microbiol.* 25 (4) (2014) 113–118.
- [3] A. Manning, S.J. Willey, J.E. Bell, P. Simmonds, Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus, *J. Infect. Dis.* 195 (9) (2007 May 1) 1345–1352.
- [4] T. Schenk, B. Maier, M. Hufnagel, B. Strahm, U. Kontny, D. Neumann-Haefelin, et al., Persistence of human bocavirus DNA in immunocompromised children, *Pediatr. Infect. Dis. J.* 30 (1) (2011 Jan) 82–84.
- [5] V. Schildgen, M. Malecki, R. Tillmann, M. Brockmann, O. Schildgen, The human bocavirus is associated with some lung and colorectal cancers and persists in solid tumors, *PLoS One* (2013) (in press).
- [6] A. Kapoor, M. Hornig, A. Asokan, B. Williams, J.A. Henriquez, W.I. Lipkin, Bocavirus episome in infected human tissue contains non-identical termini, *PLoS One* 6 (6) (2011), e21362.
- [7] X. Deng, Y. Li, J. Qiu, Human bocavirus 1 infects commercially available primary human airway epithelium cultures productively, *J. Virol. Methods* 195 (2014 Jan) 112–119.
- [8] J. Lusebrink, V. Schildgen, R.L. Tillmann, F. Wittleben, A. Bohmer, A. Muller, et al., Detection of head-to-tail DNA sequences of human bocavirus in clinical samples, *PLoS One* 6 (5) (2011), e19457.
- [9] W. Windisch, M. Pieper, I. Ziemele, J. Rockstroh, M. Brockmann, O. Schildgen, et al., Latent infection of Human Bocavirus accompanied by flare of chronic cough, fatigue, and episodes of viral replication in an immunocompetent adult patient, *Cologne, Germany, JMM Case Rep.* (2016) (ahead of print).
- [10] Q. Huang, X. Deng, Z. Yan, F. Cheng, Y. Luo, W. Shen, et al., Establishment of a reverse genetics system for studying human bocavirus in human airway epithelia, *PLoS Pathog.* 8 (8) (2012 Aug), e1002899.
- [11] R. Dijkman, S.M. Koekoek, R. Molenkamp, O. Schildgen, L. van der Hoek, Human bocavirus can be cultured in differentiated human airway epithelial cells, *J. Virol.* 83 (15) (2009 Aug) 7739–7748.
- [12] X. Deng, Z. Yan, F. Cheng, J.F. Engelhardt, J. Qiu, Replication of an autonomous human parvovirus in non-dividing human airway epithelium is facilitated through the DNA damage and repair pathways, *PLoS Pathog.* 12 (1) (2016 Jan), e1005399.
- [13] X. Deng, Z. Yan, Y. Luo, J. Xu, F. Cheng, Y. Li, et al., *In vitro* modeling of human bocavirus 1 infection of polarized primary human airway epithelia, *J. Virol.* 23 (2013 Jan).
- [14] J. Zabner, P. Karp, M. Seiler, S.L. Phillips, C.J. Mitchell, M. Saavedra, et al., Development of cystic fibrosis and noncystic fibrosis airway cell lines, *Am. J. Physiol. Lung Cell. Mol. Physiol.* 284 (5) (2003 May) L844–L854.
- [15] W. Windisch, V. Schildgen, M. Malecki, J. Lenz, M. Brockmann, C. Karagiannidis, et al., Detection of HBoV DNA in idiopathic lung fibrosis, *Cologne, Germany, J. Clin. Virol.* 58 (1) (2013 Sep) 325–327.
- [16] M. Krakau, M. Brockmann, B. Titius, C. Limmroth, S. Khalfaoui, V. Schildgen, et al., Acute human bocavirus infection in MDS patient, *Cologne, Germany, J. Clin. Virol.* 69 (2015 Aug) 44–47.
- [17] M. Krakau, K. Gerbershagen, U. Frost, M. Hinzke, M. Brockmann, V. Schildgen, et al., Case report: Human bocavirus associated pneumonia as cause of acute injury, *Cologne, Germany, Medicine* 94 (42) (2015 Oct), e1587.
- [18] J. Kaur, V. Schildgen, R. Tillmann, A.-L. Hardt, J. Lusebrink, W. Windisch, et al., Low copy number detection of HBoV DNA in BAL of asymptomatic adult patients, *Futur. Virol.* 9 (8) (2014) 715–720.
- [19] J.J. de Vries, R.G. Bredius, P.F. van Rheeën, F.J. Smiers, E.H. Scholvinck, A.C. Vossen, et al., Human bocavirus in an immunocompromised child presenting with severe diarrhea, *J. Clin. Microbiol.* 47 (4) (2009 Apr) 1241–1243.
- [20] A. Guarino, A. Giannattasio, New molecular approaches in the diagnosis of acute diarrhea: Advantages for clinicians and researchers, *Curr. Opin. Gastroenterol.* 27 (1) (2011 Jan) 24–29.
- [21] N. Chaimongkol, P. Khamrin, B. Suantai, W. Saikhreang, A. Thongprachum, R. Malasao, et al., A wide variety of diarrhea viruses circulating in pediatric patients in Thailand, *Clin. Lab.* 58 (1–2) (2012) 117–123.
- [22] H. Zhao, L. Zhao, Y. Sun, Y. Qian, L. Liu, L. Jia, et al., Detection of a bocavirus circular genome in fecal specimens from children with acute diarrhea in Beijing, China, *PLoS One* 7 (11) (2012), e48980.
- [23] V. Schildgen, M. Malecki, R.L. Tillmann, M. Brockmann, O. Schildgen, The human bocavirus is associated with some lung and colorectal cancers and persists in solid tumors, *PLoS One* 8 (6) (2013), e68020.
- [24] A.S. Abdel-Moneim, H.A. El-Fol, M.M. Kamel, A.S. Soliman, E.A. Mahdi, A.S. El-Gammal, et al., Screening of human bocavirus in surgically excised cancer specimens, *Arch. Virol.* (2016 May 7).
- [25] E.T. Martin, J. Kuypers, J.P. McRoberts, J.A. Englund, D.M. Zerr, Human bocavirus 1 primary infection and shedding in infants, *J. Infect. Dis.* 212 (4) (2015 Aug 15) 516–524.
- [26] C.L. Byington, K. Ampofo, C. Stockmann, F.R. Adler, A. Herbener, T. Miller, et al., Community surveillance of respiratory viruses among families in the Utah better identification of germs-longitudinal viral epidemiology (BIG-LoVE) study, *Clin. Infect. Dis.* 4 (2015 Aug).
- [27] O. Schildgen, V. Schildgen, Respiratory infections with human bocavirus, *Clin. Infect. Dis.* 62 (1) (2016 Jan 1) 134.